Actively Recruiting
Study of Tirzepatides Effects on Liver Health in Adults With MASLD and Obesity
Led by University of New Mexico · Updated on 2026-07-15
8
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Metabolic Dysfunction-Associated Steatotic Liver Disease MASLD is a common chronic liver condition that mainly affects people with overweight, obesity, type 2 diabetes, or cardiovascular disease. Researchers are studying how tirzepatide, a medication used for type 2 diabetes and obesity, impacts liver health in patients with MASLD through this early phase 1 clinical trial. Participants will receive tirzepatide for 12 months as part of the intervention. They will attend clinic visits every 3 months during the study. At the start, 6 months, and 12 months, blood samples will be collected. Liver ultrasounds will be performed at the beginning of the study and again at 12 months to assess liver condition. Throughout the study, participants will be monitored with blood tests and imaging to measure biomarkers related to MASLD, liver fat content, liver stiffness, body weight, and other metabolic markers. The trial involves regular clinic visits every 3 months for one year, with detailed assessments to evaluate the effects of tirzepatide on liver health and metabolism.
CONDITIONS
Brief Title
Effect of Tirzepatide on Markers of MASLD in Patients With Obesity
Research Team
K
Kristen Gonzales, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
